查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1301062

亨廷頓病治療市場規模、份額和趨勢分析報告：按療法、最終用途、地區、細分市場趨勢，2023-2030 年

Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Treatment, Disease-Modifying Therapies), By End use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

亨廷頓病治療市場增長和趨勢

根據 GrandView Research, Inc. 的最新報告，到 2030 年，全球亨廷頓舞蹈症治療市場預計將達到 18.712 億美元。

從 2023 年到 2030 年，市場預計將以 23.20% 的複合年增長率擴張。 這一增長歸因於西方國家對新產品開發、研究合作的高研發投入以及高HD負擔。 亨廷頓舞蹈症是一種罕見的遺傳性神經退行性疾□□病，影響幾代人。 發病年齡為 30 歲至 50 歲，會損害工作和照顧家庭成員的能力，最終導致無法執行日常任務。

不同地區的患病率差異超過10倍，這被認為與病例掌握和診斷標準的差異有關。 不同地理位置的患病率差異超過 10 倍，這可能與病例識別和診斷標準的差異有關。 因此，一般人群中復發性肥大的患病率可能高於預期。 亞洲的患病率一直較低，而北美和澳大利亞的患病率較高。

Neurocrine Biosciences, Inc. 和 Azevan Pharmaceuticals, Inc. 等大公司專注於 HD 對症治療的研究和開發。 Azevan Pharmaceuticals 正在開發 SRX246 作為治療亨廷頓病神經精神症狀的實驗藥物。 SRX246 是一種通過阻斷大腦中加壓素 1a (V1a) 受體發揮作用的藥物。 在神經系統中，V1a 受體是主要的加壓素受體。 通過抑制 V1a 受體，SRX246 限制加壓素與受體的結合，導致亨廷頓病患者出現煩躁和攻擊性行為。

然而，目前批准的藥物是對症和姑息治療，而不是治療疾病的根本原因。 藥物治療雖然可以減輕症狀的嚴重程度，但常伴有嗜睡、步態障礙、吞嚥困難、嗜睡等副作用，嚴重影響患者的生活質量。 鑑於這種疾病缺乏既定的治療方法，評估這些患者的健康相關生活質量 (HRQOL) 受到的影響至關重要。 早期至中期疾病的 HD 患者需要多學科醫療服務，包括認知評估和諮詢。

HD 的藥物開發麵臨重大障礙，一些治療方法未能證明療效或具有顯著的毒性。 2020 年 9 月，Vaccinex Inc. 的 pepinemab 2 期試驗未能在早期明顯和前驅期 HD 患者中達到預先指定的共同主要終點。 在 SIGNAL 試驗中，兩個共同主要終點（亨廷頓認知評估電池和臨床整體印像變化（CGIC）的兩個認知終點）在早期症狀人群中並未實現統計學顯著性增加。

亨廷頓病治療市場報告亮點

  • 由於產品可用性和專利保護，對症治療領域在 2022 年的銷售額中佔據最大份額。 由於 SAGE-718 和 Cellavita-HD 的進入，疾病緩解療法預計將成為預測期內增長最快的部分。
  • 公司現在不再針對突變蛋白，而是專注於開發通過將突變 HTT 蛋白直接注射到大腦中來直接阻斷突變 HTT 蛋白形成的療法。
  • 早期開發的新靶點藥物包括Cellavita和Azidus Brazil的Cellavita HD（幹細胞療法）、Sangamo Therapeutics的mHTT ZFP（鋅指蛋白）、AMT-130（UniQure的基因療法）等。
  • 北美地區將在 2022 年佔據最高的收入份額，並且由於美國和加拿大強大的報銷體係以及沉重的 HD 負擔，該地區將在預測期內繼續主導市場。

內容

第一章調查方法及範圍

  • 市場細分和範圍
  • 區域範圍
  • 估計/預測時間表
  • 目的
  • 調查方法
  • 信息獲取
  • 信息或數據分析
  • 市場形成和驗證
  • 型號詳細信息
  • 輔助信息列表
  • 縮寫列表

第 2 章執行摘要

  • 市場概況
  • 片段快照
  • 競爭格局快照

第三章市場變量、趨勢和範圍

  • 市場細分和範圍
  • 市場體系展望
    • 母公司市場前景
    • 相關/輔助市場前景
  • 市場趨勢和展望
  • 市場動態
    • 市場製約因素分析
    • 市場製約因素分析
  • 商業環境分析
    • SWOT 分析；按因素（政治/法律、經濟/技術）
    • 波特五力分析

第四章產品業務分析

  • 亨廷頓病治療市場：治療波動分析
  • 對症治療
  • 疾病緩解療法

第 5 章最終用戶業務分析

  • 亨廷頓病治療市場：最終用戶差異分析
    • 醫院藥房
    • 零售藥店
    • 電子商務

第 6 章區域業務分析

  • 2022 年和 2030 年亨廷頓病治療市場份額（按地區）
  • 北美
    • SWOT分析
    • 北美亨廷頓病治療市場，2018-2030
    • 美國
    • 加拿大
  • 歐洲
    • SWOT分析
    • 2018-2030 年歐洲亨廷頓病治療市場
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • SWOT分析
    • 2018-2030 年亞太地區亨廷頓舞蹈病治療市場
    • 中國
    • 印度
    • 韓國
    • 澳大利亞
    • 泰國
  • 拉丁美洲
    • SWOT分析
    • 拉丁美洲亨廷頓病治療市場，2018-2030 年
    • 巴西
    • 墨西哥
    • 阿根廷
  • MEA
    • SWOT分析
    • MEA 亨□□廷頓病治療市場，2018-2030 年
    • 南非
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 科威特

第7章競爭格局

  • 公司分類
  • 戰略規劃
  • 2022 年主要參與者的市場份額分析
  • 公司簡介
    • H. LUNDBECK A/S
    • TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • BAUSCH HEALTH COMPANIES INC.
    • HETERO
    • LUPIN
    • HIKMA PHARMACEUTICALS PLC
    • DR. REDDY'S LABORATORIES LTD.
    • SUN PHARMACEUTICAL INDUSTRIES LTD.
Product Code: GVR-2-68038-552-6

Huntington's Disease Treatment Market Growth & Trends

The global Huntington's disease treatment market size is expected to reach USD 1,871.2 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 23.20% from 2023 to 2030. This growth is due to high R&D investments for new product development, research collaboration, and the high HD burden in western countries. Huntington's disease is a rare inherited neurodegenerative disease that affects several generations. It affects people between the ages of 30 and 50, impairing their capacity to work, care for their families, and, eventually, complete daily tasks.

The prevalence varies by more than ten-fold between geographical locations, which can be related to variations in case ascertainment and diagnostic criteria. The prevalence varies by more than ten-fold between geographical locations, which can be related to variations in case ascertainment and diagnostic criteria. As a result, the prevalence of enlarged repetitions in the general population may be greater than expected. The Asian population has consistently had a lower prevalence, while Europe, North America, and Australia have a higher prevalence.

The key players, such as Neurocrine Biosciences, Inc. and Azevan Pharmaceuticals, Inc., are focusing on research and development of symptomatic therapies for HD. Azevan Pharmaceuticals is developing SRX246 as an experimental drug to treat neuropsychiatric symptoms in Huntington's disease. SRX246 is a drug that works by blocking the vasopressin 1a (V1a) receptor in the brain. In the neurological system, V1a receptor is the major vasopressin receptor. SRX246 works by inhibiting the V1a receptor, restricting vasopressin from attaching to the receptor, and generating irritable and aggressive behavior, which is seen in Huntington's disease patients.

However, currently approved drugs provide symptomatic and palliative care and do not target the underlying cause of the disease. While medications can decrease the severity of symptoms, they are often associated with adverse effects such as somnolence, gait issues, dysphagia, and apathy, which can have serious impacts on a patient's quality of life. Given the lack of a cure for the disease, it is critical to evaluate how Health-related Quality of Life (HRQOL) is affected in these patients. HD patients in early to middle stages of the disease need coordinated multidisciplinary healthcare services, including assessment of cognitive function and counseling.

Drug development for HD has faced significant obstacles as several therapies have failed to demonstrate efficacy or were associated with significant toxicity. Vaccinex Inc.'s phase II trial of Pepinemab failed to satisfy pre-specified co-primary endpoints in patients with early manifest and prodromal HD, in September 2020. The two co-primary endpoints-a family of two cognitive evaluations from the Huntington's disease Cognitive Assessment Battery and Clinical Global Impression of Change (CGIC)-did not attain statistical significance in the early manifestation population in the SIGNAL study.

Huntington's Disease Treatment Market Report Highlights

  • The symptomatic treatment segment accounted for the largest revenue share in 2022 owing to the product availability and patent protection. Disease-modifying therapies is anticipated to be the fastest-growing segment over the forecast years due to the entry of SAGE-718, and Cellavita-HD
  • Companies are now focusing on the development of treatments that can be injected directly into the brain to directly inhibit the formation of mutant HTT protein, instead of targeting the mutant protein
  • Drugs with novel targets in early-phase development include Cellavita and Azidus Brazil's Cellavita HD (stem cell therapy), Sangamo Therapeutics, Inc. mHTT ZFP (zinc finger protein), and UniQure's AMT-130 (gene therapy)
  • North America held the highest revenue share in 2022 and is expected to dominate the market over the forecast period due to better reimbursement facilities and the high burden of HD in the U.S. and Canada

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment Definitions
      • 1.1.1.1 Treatment Segment
      • 1.1.1.2 End Use Segment
  • 1.2 Regional Scope
  • 1.3 Estimates And Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 Gvr's Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary Research
  • 1.7 Information Or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
  • 1.10 List Of Secondary Sources
  • 1.11 List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation And Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends And Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Market Restraint Analysis
      • 3.4.1.1. Strong Product Pipeline
      • 3.4.1.2. Disease Burden Of Huntington's In Developed Countries
    • 3.4.2. Market Restraint Analysis
      • 3.4.2.1. Significant Challenges And Unmet Needs In Huntington's Disease Treatment
      • 3.4.2.2. High Failure Rate In Clinical Trials
  • 3.5. Business Environment Analysis
    • 3.5.1. Swot Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.5.2. Porter's Five Forces Analysis

Chapter 4. Product Business Analysis

  • 4.1 Huntington's Disease Treatment Market: Treatment Movement Analysis
  • 4.2 Symptomatic Treatment
    • 4.2.1 Symptomatic Treatment Market, 2018 - 2030 (USD Million)
  • 4.3 Disease-Modifying Therapies
    • 4.3.1 Disease-Modifying Therapies Market, 2018 - 2030 (USD Million)

Chapter 5. End User Business Analysis

  • 5.1 Huntington's Disease Treatment Market: End User Movement Analysis
    • 5.1.1 Hospital Pharmacy
      • 5.1.1.1 Hospital Pharmacy market estimates and forecast, 2018 - 2030
    • 5.1.2 Retail Pharmacy
      • 5.1.2.1 Retail Pharmacy market estimates and forecast, 2018 - 2030
    • 5.1.3 E-Commerce
      • 5.1.3.1 E-Commerce market estimates and forecast, 2018 - 2030

Chapter 6. Regional Business Analysis

  • 6.1. Huntington's Disease Treatment Market Share By Region, 2022 & 2030
  • 6.2. North America
    • 6.2.1. SWOT Analysis
    • 6.2.2. North America Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.2.3. U.S.
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Target Disease Prevalence
      • 6.2.3.3. Competitive Scenario
      • 6.2.3.4. Regulatory Framework
      • 6.2.3.5. Reimbursement Scenario
      • 6.2.3.6. U.S. Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.2.4. Canada
      • 6.2.4.1. Key Country Dynamics
      • 6.2.4.2. Target Disease Prevalence
      • 6.2.4.3. Competitive Scenario
      • 6.2.4.4. Regulatory Framework
      • 6.2.4.5. Reimbursement Scenario
      • 6.2.4.6. Canada Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Swot Analysis
    • 6.3.2. Europe Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Target Disease Prevalence
      • 6.3.3.3. Competitive Scenario
      • 6.3.3.4. Regulatory Framework
      • 6.3.3.5. Reimbursement Scenario
      • 6.3.3.6. Germany Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.3.4. UK
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Target Disease Prevalence
      • 6.3.4.3. Competitive Scenario
      • 6.3.4.4. Regulatory Framework
      • 6.3.4.5. Reimbursement Scenario
      • 6.3.4.6. UK Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.3.5. France
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Target Disease Prevalence
      • 6.3.5.3. Competitive Scenario
      • 6.3.5.4. Regulatory Framework
      • 6.3.5.5. Reimbursement Scenario
      • 6.3.5.6. France Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.3.6. Italy
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Target Disease Prevalence
      • 6.3.6.3. Competitive Scenario
      • 6.3.6.4. Regulatory Framework
      • 6.3.6.5. Reimbursement Scenario
      • 6.3.6.6. Italy Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.3.7. Spain
      • 6.3.7.1. Key Country Dynamics
      • 6.3.7.2. Target Disease Prevalence
      • 6.3.7.3. Competitive Scenario
      • 6.3.7.4. Regulatory Framework
      • 6.3.7.5. Reimbursement Scenario
      • 6.3.7.6. Spain Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.3.8. Denmark
      • 6.3.8.1. Key Country Dynamics
      • 6.3.8.2. Target Disease Prevalence
      • 6.3.8.3. Competitive Scenario
      • 6.3.8.4. Regulatory Framework
      • 6.3.8.5. Reimbursement Scenario
      • 6.3.8.6. Denmark Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.3.9. Sweden
      • 6.3.9.1. Key Country Dynamics
      • 6.3.9.2. Target Disease Prevalence
      • 6.3.9.3. Competitive Scenario
      • 6.3.9.4. Regulatory Framework
      • 6.3.9.5. Reimbursement Scenario
      • 6.3.9.6. Sweden Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.3.10. Norway
      • 6.3.10.1. Key Country Dynamics
      • 6.3.10.2. Target Disease Prevalence
      • 6.3.10.3. Competitive Scenario
      • 6.3.10.4. Regulatory Framework
      • 6.3.10.5. Reimbursement Scenario
      • 6.3.10.6. Norway Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Swot Analysis
    • 6.4.2. Asia Pacific Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Competitive Scenario
      • 6.4.3.4. Regulatory Framework
      • 6.4.3.5. Reimbursement Scenario
      • 6.4.3.6. Japan Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.4.4. China
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Competitive Scenario
      • 6.4.4.4. Regulatory Framework
      • 6.4.4.5. Reimbursement Scenario
      • 6.4.4.6. China Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.4.5. India
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Target Disease Prevalence
      • 6.4.5.3. Competitive Scenario
      • 6.4.5.4. Regulatory Framework
      • 6.4.5.5. Reimbursement Scenario
      • 6.4.5.6. India Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.4.6. South Korea
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Target Disease Prevalence
      • 6.4.6.3. Competitive Scenario
      • 6.4.6.4. Regulatory Framework
      • 6.4.6.5. Reimbursement Scenario
      • 6.4.6.6. South Korea Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.4.7. Australia
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Target Disease Prevalence
      • 6.4.7.3. Competitive Scenario
      • 6.4.7.4. Regulatory Framework
      • 6.4.7.5. Reimbursement Scenario
      • 6.4.7.6. Australia Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.4.8. Thailand
      • 6.4.8.1. Key Country Dynamics
      • 6.4.8.2. Target Disease Prevalence
      • 6.4.8.3. Competitive Scenario
      • 6.4.8.4. Regulatory Framework
      • 6.4.8.5. Reimbursement Scenario
      • 6.4.8.6. Thailand Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. SWOT Analysis
    • 6.5.2. Latin America Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.5.3. Brazil
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Competitive Scenario
      • 6.5.3.4. Regulatory Framework
      • 6.5.3.5. Reimbursement Scenario
      • 6.5.3.6. Brazil Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Competitive Scenario
      • 6.5.4.4. Regulatory Framework
      • 6.5.4.5. Reimbursement Scenario
      • 6.5.4.6. Mexico Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.5.5. Argentina
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Competitive Scenario
      • 6.5.5.4. Regulatory Framework
      • 6.5.5.5. Reimbursement Scenario
      • 6.5.5.6. Argentina Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • 6.6. MEA
    • 6.6.1. SWOT Analysis
    • 6.6.2. MEA Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.6.3. South Africa
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Competitive Scenario
      • 6.6.3.4. Regulatory Framework
      • 6.6.3.5. Reimbursement Scenario
      • 6.6.3.6. South Africa Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.6.4. Saudi Arabia
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Competitive Scenario
      • 6.6.4.4. Regulatory Framework
      • 6.6.4.5. Reimbursement Scenario
      • 6.6.4.6. Saudi Arabia Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.6.5. UAE
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Competitive Scenario
      • 6.6.5.4. Regulatory Framework
      • 6.6.5.5. Reimbursement Scenario
      • 6.6.5.6. UAE Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
    • 6.6.6. Kuwait
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Competitive Scenario
      • 6.6.6.4. Regulatory Framework
      • 6.6.6.5. Reimbursement Scenario
      • 6.6.6.6. Kuwait Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1 Company Categorization
  • 7.2 Strategy Mapping
    • 7.1.1. New Product Launch
    • 7.1.2. Partnerships
    • 7.1.3. Acquisition
    • 7.1.4. Collaboration
    • 7.1.5. Funding
  • 7.3 Key Company Market Share Analysis, 2022
  • 7.4 Company Profiles
    • 7.4.1 H. LUNDBECK A/S
      • 7.4.1.1 Company overview
      • 7.4.1.2 Financial performance
      • 7.4.1.3 Product benchmarking
      • 7.4.1.4 Strategic Initiatives
    • 7.4.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
      • 7.4.2.1 Company overview
      • 7.4.2.2 Financial performance
      • 7.4.2.3 Product benchmarking
      • 7.4.2.4 Strategic Initiatives
    • 7.4.3 BAUSCH HEALTH COMPANIES INC.
      • 7.4.3.1 Company overview
      • 7.4.3.2 Financial performance
      • 7.4.3.3 Product benchmarking
      • 7.4.3.4 Strategic Initiatives
    • 7.4.4 HETERO
      • 7.4.4.1 Company overview
      • 7.4.4.2 Product benchmarking
      • 7.4.4.3 Strategic Initiatives
    • 7.4.5 LUPIN
      • 7.4.5.1 Company overview
      • 7.4.5.2 Financial performance
      • 7.4.5.3 Product benchmarking
      • 7.4.5.4 Strategic Initiatives
    • 7.4.6 HIKMA PHARMACEUTICALS PLC
      • 7.4.6.1 Company overview
      • 7.4.6.2 Financial performance
      • 7.4.6.3 Product benchmarking
      • 7.4.6.4 Strategic Initiatives
    • 7.4.7 DR. REDDY'S LABORATORIES LTD.
      • 7.4.7.1 Company overview
      • 7.4.7.2 Financial performance
      • 7.4.7.3 Product benchmarking
      • 7.4.7.4 Strategic Initiatives
    • 7.4.8 SUN PHARMACEUTICAL INDUSTRIES LTD.
      • 7.4.8.1 Company overview
      • 7.4.8.2 Financial performance
      • 7.4.8.3 Product benchmarking
      • 7.4.8.4 Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Huntington's Disease Treatment Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 5 Global Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 6 Global Huntington's Disease Treatment Market, by Region, 2018 - 2030 (USD Million)
  • Table 7 North America Huntington's Disease Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 9 North America Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 10 U.S. Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 11 U.S. Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 12 Canada Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 13 Canada Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 14 Europe Huntington's Disease Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 15 Europe Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 16 Europe Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 17 Germany Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 18 Germany Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 19 UK Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 20 UK Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 21 France Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 22 France Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 23 Italy Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 24 Italy Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 25 Spain Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 26 Spain Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 27 Denmark Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 28 Denmark Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 29 Sweden Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 30 Sweden Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 31 Norway Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 32 Norway Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Huntington's Disease Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 36 China Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 37 China Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 38 Japan Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 39 Japan Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 40 India Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 41 India Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 42 South Korea Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 43 South Korea Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 44 Australia Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 45 Australia Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 46 Thailand Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 47 Thailand Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 48 Latin America Huntington's Disease Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 49 Latin America Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 50 Latin America Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 51 Brazil Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 52 Brazil Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 53 Mexico Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 54 Mexico Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 55 Argentina Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 56 Argentina Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Huntington's Disease Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 59 Middle East & Africa Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 60 South Africa Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 61 South Africa Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 63 Saudi Arabia Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 64 UAE Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 65 UAE Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 67 Kuwait Huntington's Disease Treatment Market, by End use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain - Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Huntington's Disease Treatment Market Segmentation
  • Fig. 8 Market Snapshot, 2022
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Global Huntington's Disease Treatment Market: by Treatment Movement Analysis
  • Fig. 15 Global Huntington's Disease Treatment Market, for Symptomatic treatment, 2018 - 2030 (USD Million)
  • Fig. 16 Global Huntington's Disease Treatment Market, for Disease - modifying therapies, 2018 - 2030 (USD Million)
  • Fig. 17 Global Huntington's Disease Treatment Market: End use Movement Analysis
  • Fig. 18 Global Huntington's Disease Treatment Market, for Pharmaceutical & Biotechnology Companies, 2018 - 2030 (USD Million)
  • Fig. 19 Global Huntington's Disease Treatment Market, for Hospital pharmacy, 2018 - 2030 (USD Million)
  • Fig. 20 Global Huntington's Disease Treatment Market, for Retail pharmacy, 2018 - 2030 (USD Million)
  • Fig. 21 Global Huntington's Disease Treatment Market, for E - commerce, 2018 - 2030 (USD Million)
  • Fig. 22 Regional Marketplace: Key Takeaways Huntington's Disease Treatment Market, Region 2018 - 2030 (USD Million)
  • Fig. 23 Huntington's Disease Treatment Market :Regional Outlook, 2022 & 2030 2018 - 2030 (USD Million)
  • Fig. 24 North America Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 26 Canada Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 27 Europe Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 28 Germany Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 29 UK Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 30 France Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 31 Italy Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 32 Spain Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 33 Denmark Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 34 Sweden Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 35 Norway Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 36 Asia Pacific Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 37 Japan Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 38 China Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 39 India Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 40 Australia Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 41 South Korea Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 42 Thailand Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 43 Latin America Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 44 Brazil Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 45 Mexico Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 46 Argentina Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 47 Middle East and Africa Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 48 South Africa Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 49 Saudi Arabia Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 50 UAE Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 51 Kuwait Huntington's Disease Treatment Market, 2018 - 2030 (USD Million)